GeneDx (WGS) to Release Earnings on Tuesday

GeneDx (NASDAQ:WGS - Get Free Report) will post its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect GeneDx to post earnings of ($0.19) per share for the quarter. GeneDx has set its FY 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.15. The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $58.90 million. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. On average, analysts expect GeneDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GeneDx Trading Down 0.7 %

WGS stock traded down $0.40 during trading on Tuesday, hitting $57.79. The company had a trading volume of 232,291 shares, compared to its average volume of 418,157. The firm has a market capitalization of $1.51 billion, a P/E ratio of -11.22 and a beta of 2.32. GeneDx has a 52-week low of $1.16 and a 52-week high of $61.96. The company has a 50 day simple moving average of $41.34 and a 200-day simple moving average of $29.89. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27.

Insider Activity

In other news, major shareholder Opko Health, Inc. sold 60,000 shares of the firm's stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $33.85, for a total value of $2,031,000.00. Following the sale, the insider now directly owns 3,123,403 shares in the company, valued at approximately $105,727,191.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Opko Health, Inc. sold 60,000 shares of GeneDx stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $33.85, for a total value of $2,031,000.00. Following the completion of the sale, the insider now directly owns 3,123,403 shares in the company, valued at $105,727,191.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 3,639 shares of GeneDx stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $121,287.87. Following the completion of the sale, the chief executive officer now owns 95,457 shares of the company's stock, valued at $3,181,581.81. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 543,668 shares of company stock worth $18,104,988. Corporate insiders own 28.10% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of GeneDx in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $34.00 price target on the stock. Craig Hallum raised their price target on shares of GeneDx from $43.00 to $46.00 and gave the stock a "buy" rating in a research note on Wednesday, July 31st. The Goldman Sachs Group raised their price target on shares of GeneDx from $32.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 16th. BTIG Research raised their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Finally, TD Cowen raised their target price on shares of GeneDx from $46.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $41.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.